What the research shows: Chronic ipamorelin treatment increases the volume density of secretion granules in somatotroph cells and modulates intracellular GH content, demonstrating that sustained dosing produces cumulative pituitary-level changes rather than just transient GH spikes (Jimenez-Reina et al., 2002)
Overexpression of pS6, mTOR activation, calcitonin, and C-cell hyperplasia reported in in vivo suggest the increased proliferation and tumorigenesis [75, 87]
Very important is improving glycemic control as well as lipid and blood pressure control
(accessed 10/4/2021, 2021)
These findings underscore the potential of peptide therapy in enhancing recovery outcomes and overall wellness therapy
Subsequent studies aimed to refine the dosage for a more controlled response, eventually settling around 1.25 mg to achieve an erection upon additional sexual stimuli